We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 10, 2022

Acalabrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

British Journal of Haematology


Additional Info

British Journal of Haematology
A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma
Br. J. Haematol 2022 Jul 21;[EPub Ahead of Print], P Strati, M Coleman, R Champion, S Ma, C Patti, MY Levy, IS Lossos, PR Geethakumari, S Lam, R Calvo, K Higgins, LE Budde

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading